-
Rituxan for the Treatment of Non-Hodgkin’s Lymphoma, US
23 Apr 2024 17:29 GMT
… skin.
Rituxan was developed by Biogen Idec, a biotechnology company based in … Chugai Pharmaceutical. In Roche’s pipeline, Rituxan is the second largest …
-
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr.…
23 Apr 2024 12:00 GMT
… Recludix, we have a robust pipeline of validated targets, starting with … positions at Amgen Inc. and Biogen Idec where he was involved in …
-
Tiny brain bubbles carry complete codes
09 Apr 2024 01:35 GMT
… Pharmaceuticals, Arena Pharmaceuticals, Autobahn Therapeutics, Biogen Idec, BrainStorm Cell Therapeutics, Bristol Myers … , Novartis Pharmaceuticals, Ono Pharmaceuticals, Pfizer, Pipeline Therapeutics, RuiYi, ShouTi, Simulyve International …
-
ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
02 Apr 2024 13:05 GMT
… ADARx's expanding pipeline of RNA targeting therapeutics, … in steering our robust pipeline of next-generation RNA … medical initiatives for all pipeline candidates and four marketed … increasingly responsible positions at Biogen-Idec and Amgen. Prior to …
-
Global Chronic Lymphocytic Leukemia Therapeutics Market Research Report to 2027 - Introduction of Novel Therapy Drugs and Availability of Several Pipeline Drugs Presents Opportunities - ResearchAndMarkets.com
16 Jun 2022 18:24 GMT
… drugs and availability of several pipeline drugs
Availability of therapeutics through … , Inc.
Amgen, Inc.
AstraZeneca PLC
Biogen Idec Inc
Boehringer Ingelheim International GmbH …
-
Dementia Drugs Market Trends : The Hospitals pharmacies is Projected to Grow at a CAGR of 7.0% During 2021-2031
18 Mar 2024 07:13 GMT
… ;D by industry players, robust pipeline candidates, enhanced public awareness about …
Apotex inc.
Aurobindo Pharma Ltd.
Biogen Idec
Eisai
Eli Lilly and Company …
-
Anti-Lymphotoxin - Pipeline Insight Report 2018 Featuring Roche, Zydus, Amgen & Biogen Idec - ResearchAndMarkets.com
24 Aug 2018 20:11 GMT
DUBLIN--(BUSINESS WIRE)--Aug 24, 2018--The "Anti-Lymphotoxin -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Anti-Lymphotoxin - Pipeline Insight, 2018' report offers comprehensive insights …
-
Zymeworks Announces Appointment Of Dr. Alessandra Cesano To Its Board Of Directors
05 Mar 2024 18:01 GMT
… biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics … Inc., Biogen Inc. (formerly Biogen Idec) and SmithKline Beecham Pharmaceuticals, where … partners; Zymeworks' preclinical pipeline; the expected benefits of the …
-
Non Hodgkin’s Lymphoma Market to Reach US$ 7.4 Billion by 2034, at CAGR of 5.71% from 2024 to 2034
27 Feb 2024 09:14 GMT
… marketed drugs and late-stage pipeline drugs.
In-Market Drugs:
• Drug … and Market Performance
Late-Stage Pipeline Drugs:
• Drug overview
• Mechanism of … Biopharma /Biogen
Gilead Sciences
Biogen Idec/Genentech
Sanofi
Ask Analyst …
-
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
08 Feb 2024 11:09 GMT
… biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics … Inc., Biogen Inc. (formerly Biogen Idec) and SmithKline Beecham Pharmaceuticals, where … to Zymeworks’ wholly owned pipeline, its therapeutic platforms have …